ReviewEndocrine2019
Epithelial-to-mesenchymal transition in thyroid cancer: a comprehensive review.
Review in Endocrine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 103 citations in OpenAlex.
- Spatial and single-nuclei transcriptomics reveals idiosyncratic and generic patterns in papillary and anaplastic thyroid cancers.Molecular oncology · 2026Article
- Exploratory Machine Learning and Omics Integration in the Search for Biomarkers of Papillary Thyroid Cancer.Biology · 2026Article
- Single-cell reveals age-dependent epithelial reprogramming and EMT vulnerability in THCA.Endocrine-related cancer · 2026Article
- Visualizing malignant progression: in situ CD109-based spatial immunofluorescence assay delineates papillary to anaplastic thyroid carcinoma transformation within the tumor microenvironment.Scientific reports · 2026Article
- Anaplastic Thyroid Carcinoma and High-Grade Tall Cell Papillary Thyroid Carcinoma: Case Report of a Rare Association.Reports (MDPI) · 2026Article
- Cancer-associated fibroblasts as a potential therapeutic target for thyroid cancers.International journal of surgery (London, England) · 2026Review
- The significance of epithelial-mesenchymal transition (EMT) in the initiation, plasticity, and treatment of glioblastoma.Genes & diseases · 2026Review
- Investigating the potential anti-cancer mechanism for thyroid cancer: Role of Herba Epimedii via network pharmacology approach.Journal, genetic engineering & biotechnology · 2025Article
- Article
- ZNF217 Mediates Transcriptional Activation of GRHL3 to Regulate SLC22A31 and Promote Malignant Progression in Thyroid Cancer.Molecular biotechnology · 2025Article
- Article
- Sesquiterpene Lactones as Promising Phytochemicals to Cease Metastatic Propagation of Cancer.Biomolecules · 2025Review
- ARNTL2: a key player in promoting tumor aggressiveness in papillary thyroid cancer.Translational cancer research · 2025Article
- PTEN inhibits epithelial mesenchymal transition of thyroid cancer cells by regulating the Wnt/β-Catenin signaling pathway.Discover oncology · 2024Article
- High expression of COL8A1 predicts poor prognosis and promotes EMT in papillary thyroid cancer.Endocrine connections · 2024Article
- CircRNA ITCH Inhibits Epithelial-Mesenchymal Transformation and Promotes Apoptosis in Papillary Thyroid Carcinoma via miR-106a-5p/JAZF1 Axis.Biochemical genetics · 2024Article
- Benzyl isothiocyanate suppresses development of thyroid carcinoma by regulating both autophagy and apoptosis pathway.iScience · 2024Article
- Tight Junctions and Cancer: Targeting Claudin-1 and Claudin-4 in Thyroid Pathologies.Pharmaceuticals (Basel, Switzerland) · 2024Article
- GNA15 facilitates the malignant development of thyroid carcinoma cells via the BTK-mediated MAPK signaling pathway.Histology and histopathology · 2024Article
- Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model.Cancer cell international · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Metastatic progression of solid tumors, such as thyroid cancer is a complex process which involves various factors. Current understanding on the role of epithelial-mesenchymal transition (EMT) in thyroid carcinomas suggests that EMT is implicated in the progression from follicular thyroid cancer (FTC) and papillary thyroid cancer (PTC) to poorly differentiated thyroid carcinoma (PDTC) and anaplastic thyroid cancer (ATC). According to the literature, the initiation of the EMT program in thyroid epithelial cells elevates the number of stem cells, which contribute to recurrent and metastatic diseases. The EMT process is orchestrated by a complex network of transcription factors, growth factors, signaling cascades, epigenetic modulations, and the tumor milieu. These factors have been shown to be dysregulated in thyroid carcinomas. Therefore, molecular interferences restoring the expression of tumor suppressors, or thwarting overexpressed oncogenes is a hopeful therapeutic method to improve the treatment of progressive diseases. In this review, we summarize the recent findings on EMT in thyroid cancer focusing on the main role-players and regulators of this process in thyroid tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.